BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard Sells 1,577 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 1,577 shares of the business’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the sale, the chief marketing officer now directly owns 104,961 shares in the company, valued at $2,624,025. This trade represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Todd Berard also recently made the following trade(s):

• On Monday, March 3rd, Todd Berard sold 424 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total value of $10,795.04.
• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $9,267.86.

BioLife Solutions Stock Down 0.2 %

BioLife Solutions stock opened at $25.00 on Friday. The stock has a market cap of $1.18 billion, a PE ratio of -23.58 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55. The stock has a fifty day moving average of $26.62 and a 200 day moving average of $25.50.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. The company had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same quarter in the prior year, the business earned ($0.21) earnings per share. As a group, sell-side analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Institutional Trading of BioLife Solutions

A number of hedge funds have recently bought and sold shares of BLFS. Steward Partners Investment Advisory LLC purchased a new stake in BioLife Solutions during the fourth quarter valued at $26,000. Mark Sheptoff Financial Planning LLC bought a new stake in BioLife Solutions during the third quarter valued at about $28,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in BioLife Solutions during the fourth quarter valued at about $31,000. Quest Partners LLC bought a new stake in BioLife Solutions during the third quarter valued at about $57,000. Finally, 1620 Investment Advisors Inc. grew its holdings in BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 675 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Northland Securities boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday, January 8th. HC Wainwright boosted their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. KeyCorp boosted their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, Benchmark restated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.